Asciminib

Asciminib is an orally administered targeted anticancer medicine belonging to the BCR::ABL1 tyrosine kinase inhibitor class. Unlike conventional ATP-competitive tyrosine kinase inhibitors, asciminib specifically binds to the myristoyl pocket of the BCR::ABL1 protein and restores an inhibitory conformation of the kinase. This distinct mechanism provides targeted inhibition of the abnormal BCR::ABL1 signaling responsible for Philadelphia chromosome-positive chronic myeloid leukemia. Asciminib is used in adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including selected patients with newly diagnosed disease and patients previously treated with other tyrosine kinase inhibitors. It is also used for chronic-phase disease carrying the T315I mutation in appropriate treatment settings. Asciminib is administered orally as tablets and can be given at 80 mg once daily or 40 mg twice daily for most approved CML-CP indications under the current U.S. prescribing information, while the T315I mutation indication uses a higher dose of 200 mg twice daily. Treatment is generally continued until disease progression or unacceptable toxicity. Monitoring is important because asciminib can cause myelosuppression, pancreatic enzyme abnormalities, hypertension, hypersensitivity reactions and cardiovascular toxicity, while laboratory monitoring is also used to assess treatment response through BCR::ABL1 molecular testing.

Asciminib was developed as a first-in-class STAMP inhibitor, meaning a specifically targeted inhibitor of the ABL myristoyl pocket, designed to inhibit BCR::ABL1 through a binding site distinct from that used by conventional ATP-competitive tyrosine kinase inhibitors. The U.S. Food and Drug Administration granted accelerated approval on 29 October 2021 for adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase previously treated with at least two tyrosine kinase inhibitors and for adults with Ph+ CML-CP carrying the T315I mutation. FDA granted accelerated approval on 29 October 2024 for adults with newly diagnosed Ph+ CML-CP and for an additional previously treated CML-CP population. The newly diagnosed indication was supported by the phase 3 ASC4FIRST trial, while the previously treated setting was supported by clinical studies including ASCEMBL and related follow-up analyses. In the European Union, Scemblix received marketing authorisation on 25 August 2022 for adults with Ph+ CML in chronic phase and for patients with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib. Indian CDSCO records document approval of asciminib tablets, including 20 mg and 40 mg strengths, and subsequent regulatory permission concerning a 100 mg additional strength in 2025. Key clinical programmes include ASCEMBL, CABL001A2301 and ASC4FIRST.

Asciminib is used for adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. In the United States, current indications include newly diagnosed Ph+ CML-CP, previously treated Ph+ CML-CP and Ph+ CML-CP with the T315I mutation. In the newly diagnosed setting, asciminib is used as frontline therapy for adults with Ph+ CML-CP, while in previously treated disease it can be used according to the applicable treatment history and regulatory indication. For patients with the T315I mutation, asciminib is used at a higher dose and provides an option for a molecular subtype associated with resistance to several conventional BCR::ABL1 inhibitors. European regulatory indications include adults with Ph+ CML-CP and adults with Ph+ CML-CP carrying the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib. Treatment selection should consider disease phase, BCR::ABL1 mutation status, previous tyrosine kinase inhibitor exposure, treatment response, cardiovascular and pancreatic risk factors, concomitant medicines and the approved indication applicable to the specific jurisdiction.

Asciminib is administered orally. For adults with newly diagnosed or previously treated Ph+ CML in chronic phase under the current U.S. prescribing information, the recommended dose is 80 mg once daily at approximately the same time each day or 40 mg twice daily at approximately 12-hour intervals. For adults with Ph+ CML-CP carrying the T315I mutation, the recommended U.S. dose is 200 mg twice daily. Asciminib should be taken on an empty stomach, with no food for at least two hours before and one hour after administration, and tablets should be swallowed whole without breaking, crushing or chewing them. Treatment is generally continued until disease progression or unacceptable toxicity. Dose interruption, reduction or discontinuation may be required for significant myelosuppression, pancreatic toxicity, uncontrolled hypertension, hypersensitivity, cardiovascular toxicity or clinically important drug interactions. Molecular response should be monitored using appropriate BCR::ABL1 testing to assess treatment effectiveness and guide long-term management.

Common side effects of asciminib include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain and diarrhea. Other adverse effects may include nausea, vomiting, cough, constipation, joint pain and fluid accumulation around the lungs. Laboratory abnormalities can include reduced lymphocyte, leukocyte, platelet and neutrophil counts, increased lipase and amylase, changes in liver enzymes, reduced hemoglobin and alterations in calcium, cholesterol, uric acid and triglyceride levels. In patients with the T315I mutation, pancreatic enzyme abnormalities, abdominal symptoms and other treatment-related effects may occur more frequently or require particular attention. The frequency and severity of adverse reactions vary according to treatment setting, dose, duration of therapy and individual patient factors. Many non-serious adverse effects can be managed with clinical observation, supportive care, laboratory monitoring, treatment interruption or dose modification under medical supervision.

Important serious risks associated with asciminib include severe myelosuppression, pancreatic toxicity, hypertension, hypersensitivity reactions and cardiovascular toxicity. Thrombocytopenia and neutropenia can increase the risk of bleeding and infection and require regular complete blood-count monitoring. Asciminib can increase serum lipase and amylase and may cause pancreatitis, particularly when abdominal pain or other compatible symptoms accompany marked enzyme elevations. Blood pressure should be monitored during treatment because clinically significant hypertension can require treatment modification. Cardiovascular toxicity may include ischemic or other cardiovascular events, particularly in patients with relevant baseline risk factors. Hypersensitivity reactions can require prompt treatment and, depending on severity, interruption or permanent discontinuation. Asciminib can cause fetal harm, and appropriate pregnancy precautions are required. Patients should be monitored for clinically significant laboratory abnormalities and symptoms throughout therapy.

Before starting asciminib, healthcare professionals should confirm Philadelphia chromosome-positive CML and assess disease phase, previous tyrosine kinase inhibitor exposure and, where clinically relevant, BCR::ABL1 mutation status. Baseline assessment should include complete blood counts, pancreatic enzymes, liver function, renal function, blood pressure and cardiovascular history. Complete blood counts should be monitored regularly, while serum lipase and amylase should be monitored during treatment and when symptoms suggest pancreatic toxicity. Asciminib is metabolized through CYP3A4 and can interact with medicines that affect CYP3A4 activity. Strong CYP3A4 inhibitors require close monitoring for adverse reactions at higher asciminib doses, while certain CYP3A4 substrates may require additional monitoring or avoidance depending on the asciminib dose. CYP2C9 substrates and certain P-glycoprotein or BCRP substrates also require careful medication review. Rosuvastatin and other BCRP substrates may require particular attention because asciminib can affect their exposure. Breastfeeding is not recommended during treatment, and effective contraception should be discussed with patients who may become pregnant.

Prescribers should confirm the CML disease phase, Philadelphia chromosome status, prior tyrosine kinase inhibitor history and relevant BCR::ABL1 mutation information before initiating asciminib. Baseline assessment should include complete blood count, blood pressure, pancreatic enzymes, liver and kidney function and cardiovascular risk evaluation. Molecular monitoring of BCR::ABL1 transcript levels is important for assessing response and detecting inadequate molecular control or loss of response. Patients should be counselled to report unusual bleeding, fever, persistent infection, severe abdominal pain, nausea, vomiting, severe headache, chest discomfort, shortness of breath, palpitations or symptoms of hypersensitivity promptly. Pharmacists should verify whether the prescribed regimen is once-daily, twice-daily or the higher T315I dose, as well as the fasting administration requirements and formulation strength. Medication reconciliation should specifically review CYP3A4, CYP2C9, P-glycoprotein and BCRP interactions. Coordination between hematology, oncology, pharmacy and laboratory teams helps maintain molecular-response monitoring and identify toxicity early.